First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
暂无分享,去创建一个
Hyae-Young Kim | J. Ahn | M. Ahn | Keunchil Park | Sang-We Kim | Heung Tae Kim | Dae-Ho Lee | Ji-Youn Han | C. Suh | J. S. Lee | Keunchil Park | Cheolwon Suh | Jung-Shin Lee | Sang-We Kim | Ji-Youn Han | Dae Ho Lee | Hyae Young Kim | Heung Tae Kim | Myung Ju Ahn | Tak Yun | Jin Seok Ahn | Sung Jin Yoon | Jong Hee Han | Jae Won Lee | Sook Jung Jo | Jin Soo Lee | T. Yun | Jung-shin Lee | Jong Hee Han | Sook Jung Jo | Jae Won Lee | S. Yoon | Sung Jin Yoon
[1] L. Tanoue,et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .
[2] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[3] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[4] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[5] M. Loda,et al. Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer , 2009, Clinical Cancer Research.
[6] S. Novello,et al. Lung cancer in never smokers: a different disease , 2014, Current Respiratory Care Reports.
[7] S. Toyooka,et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] A. Sasse,et al. Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis. , 2009, European journal of cancer.
[9] N. Rekhtman,et al. Advances in Fine Needle Aspiration Cytology for the Diagnosis of Pulmonary Carcinoma , 2011, Pathology research international.
[10] Hyae-Young Kim,et al. The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] Sébastien Couraud,et al. Lung cancer in never smokers--a review. , 2012, European journal of cancer.
[12] E. Felip,et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Gazdar,et al. Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.
[14] Gregory J Riely,et al. Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials , 2009, Clinical Cancer Research.
[15] L. Tanoue. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .
[16] E. Tan,et al. Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients , 2005, British Journal of Cancer.
[17] Joon-Oh Park,et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Meyerson,et al. Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients , 2006, Clinical Cancer Research.
[19] S. Kaasa,et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. , 1994, European journal of cancer.
[20] William Pao,et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Grothey,et al. Similarities in treatment (Tx) patterns and clinical outcomes (CO) in patients (pts) with metastatic colorectal cancer (mCRC) initially treated with FOLFOX/BV or FOLFIRI/BV: Results from ARIES, a bevacizumab (BV) observational study. , 2011, Journal of Clinical Oncology.
[22] Y. Wu,et al. Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] S. Digumarthy,et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] N. Hanna,et al. EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .
[25] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[26] Hyae-Young Kim,et al. Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers , 2005, Clinical Cancer Research.